CytoDyn Inc. (CYDY)
| Previous close | 0.3275 |
| Open | 0.3300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.3020 - 0.3300 |
| 52-week range | 0.2300 - 2.5400 |
| Volume | |
| Avg. volume | 2,381,780 |
| Market cap | 230.94M |
| Beta (5Y monthly) | -0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2250 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
VANCOUVER, Wash., January 25, 2022--Today the Board of Directors ("the Board") of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a leadership transition plan. Effective immediately, Antonio Migliarese, currently CytoDyn’s Chief Financial Officer, has been appointed interim President. The Board of Directors terminated the employment of Nader Z. Pourhassan,
- Business Wire
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
VANCOUVER, Wash., January 13, 2022--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.
- Business Wire
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced ("HTE") Subjects
VANCOUVER, Wash., January 10, 2022--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that a research paper entitled "Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects" has been accepted, peer reviewed and is available as a journal pre-proof on ScienceDirect. ScienceDirect provides
